Articles tagged with Thrombosis
Researchers at the University of Utah will investigate the molecular causes of blood clots, which threaten millions of people worldwide. The center aims to apply basic science to find new diagnostic and therapeutic measures for thrombosis, making them available to patients rapidly.
Researchers have discovered a promising compound that inhibits clotting in the bloodstream without triggering excessive bleeding. PAMAM G-3, an experimental compound, prevents activation of the process leading to blood clot formation while maintaining normal blood clotting factors.
Researchers measured environmental air pollutants and biomarkers for systemic inflammation and thrombosis before, during, and after the 2008 Olympics. Concentrations of particulate and gaseous pollutants decreased substantially, but ozone concentrations increased.
Researchers at Beth Israel Deaconess Medical Center have identified a flavonoid compound called rutin as a potential therapeutic agent to prevent the formation of blood clots. Rutin was shown to inhibit thrombosis in an animal model, offering a novel strategy for preventing stroke and heart attack.
A study published in JAMA found that fish oil supplementation did not decrease graft patency but reduced thrombosis rates and clinical interventions. The study showed a significant reduction in thrombosis events and radiological interventions in patients receiving fish oil, but no difference in graft loss.
Researchers found that aggressive treatment for chronic DVT can restore blood flow and improve quality of life for those with post-thrombotic syndrome. Minimally invasive procedures like angioplasty, stenting, and thrombolytic therapy showed promising technical and clinical outcomes.
A long-term study found elevated mortality rates among individuals who experienced venous thrombosis or pulmonary embolism compared to controls. The research, published in PLoS Medicine, underscores the major consequences of venous thrombosis on both morbidity and mortality.
The study found that new generation drug-eluting stents were associated with a 28% lower risk of mortality, compared to old generation DES, and a 23% lower mortality rate at two years. The new generation DES also had a 38% lower risk of restenosis and a 43% lower risk of stent thrombosis within two years.
A study has discovered four gene variants that contribute to early stent thrombosis in people with coronary artery disease. These variants affect blood thinner clopidogrel sensitivity and platelet receptor function, increasing the risk of deadly complications after stent implantation.
A study found that patients with certain genetic variants related to clopidogrel metabolism and platelet function are at higher risk of developing blood clots within coronary stents. The researchers identified three key genetic factors and two modifiable clinical factors that increase the risk of early stent thrombosis
The EXAMINATION trial found a non-significant trend towards benefit with Xience-V stent, resulting in a lower rate of new revascularisations and significantly lower rates of definite and probable stent thrombosis at one-year follow-up.
A nationwide study in Sweden found that new generation drug eluting stents reduced the risk of clinically meaningful restenosis by 38% and stent thrombosis by 50% compared to older generation stents. The study included data from over 90,000 patients and showed improved outcomes with thinner struts and more biocompatible polymers.
The Bern-Rotterdam cohort study found a 67% risk reduction in very late stent thrombosis for patients treated with everolimus-eluting stents compared to early generation drug-eluting stents. This is an important advance in the safety of drug-eluting stents.
A pharmacist-directed anticoagulation service improves the transition of care for patients treated with warfarin, enhancing communication between hospital and outpatient clinicians. The study found a 5% decline in bleeding and thrombosis risk for patients treated by the service.
A new trial shows that standard-dose clopidogrel is as effective as double the dose for preventing cardiovascular events in patients with high on-treatment platelet reactivity. Researchers argue that a personalized approach to antiplatelet therapy may be more beneficial, warranting further investigation.
Deep vein thrombosis (DVT) affects millions worldwide, leading to post-thrombotic syndrome and pulmonary embolism. Interventional radiologists have developed clot-busting treatments that can dissolve large blood clots with minimal risk, offering new hope for patients.
A study of 2,214 patients found that high-dose clopidogrel did not reduce the risk of nonfatal heart attack, stent thrombosis, or cardiovascular death compared to standard-dose therapy. The treatment strategy for patients with high platelet reactivity remains undefined.
Recent research suggests that liver resection patients are at risk of developing hepatic vein thrombosis, which can lead to pulmonary embolism. The study reports two cases where thrombi formed in hepatic veins following surgery.
Researchers at UT Southwestern Medical Center have identified the molecular mechanisms underlying antiphospholipid syndrome (APS), a potentially life-threatening condition that causes blood clots. The study's findings suggest that targeting specific proteins may lead to new therapies for APS and its associated pregnancy complications.
A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at 6 months, according to a study led by Laura Mauri, MD. The bioresorbable polymer and stent design showed better clinical outcomes and reduced stent thrombosis risk without compromising anti-restenotic efficacy.
Research reveals a significant association between sleep-disordered breathing and cardiovascular disease, with pro-thrombotic biomarkers PAI-1 and fibrinogen showing increases in relation to SDB severity. The study suggests that even mild levels of SDB may pose an enhanced risk for cardiovascular disease.
A review of 1098 studies found that pregnant women are more likely to develop deep vein thrombosis (DVT) on the left side, particularly in the left leg. The study suggests that routine examination of the iliofemoral system may be prudent when diagnosing DVT in pregnant patients.
The SORT OUT III study found that sirolimus-eluting stents are superior to zotarolimus-eluting stents for patients with complex lesions, halving the risk of major adverse cardiac events within 9 months. The difference persisted at 18 months, with a lower need for repeat revascularisation and reduced risk of heart attack.
Researchers have discovered a blood clotting agent that can be targeted without affecting normal wound healing, offering potential improvements over existing anticoagulant drugs. The findings suggest polyphosphate or factor XII could be new targets for drug development to reduce thrombosis risk.
A Massachusetts General Hospital study found no evidence of deep venous thrombosis in most trauma patients with pulmonary embolism, questioning the current understanding of the condition's origin. The researchers suggest that clots may form independently in the lungs, potentially revolutionizing the way PE is prevented and treated.
Researchers studied 247 trauma patients with lung blood clots and found no association between the two conditions. The study suggests that many pulmonary embolisms form primarily in the lungs, contradicting decades-long teaching that deep venous thrombosis is a precursor to pulmonary embolism.
A recent study published in Critical Care found that severe trauma patients who receive old red blood cells are twice as likely to die. The study, which analyzed data from 202 patients, suggests that using fresher red blood cells may reduce mortality rates and complications.
Concurrent deep vein thrombosis is more likely when superficial vein thrombosis affects the lower leg, according to a study published in Archives of Dermatology. The study found that 24% of patients with superficial vein thrombosis also had deep vein thrombosis.
A study found that children and siblings of individuals with venous thrombosis have a higher risk of developing the condition. Family history was associated with a more than two-fold increase in risk, even if no known genetic factors were present.
The European Society of Cardiology has reaffirmed its advice on cardiovascular risks associated with long-haul flights. Studies suggest that flight duration exceeding four hours increases the risk of venous thromboembolism (VTE) due to immobility, dehydration, and reduced oxygen in the cabin.
Researchers found that adjusting warfarin doses only when the international normalized ratio is between 1.7 and 3.3 improves patient outcomes. The study used a model to predict optimal dose changes based on clinic visits and anticoagulation control, revealing that patients deviating from predicted changes had worse control.
A study of 387 patients found that 43% developed postthrombotic syndrome, a long-term complication not addressed by traditional treatment approaches. The risk factors identified include age, previous DVT, and larger blood clots at diagnosis.
The 12-month ATLANTA Trial data showed zero percent stent thrombosis in patients discontinuing dual anti-platelet therapy after 30 days. The CATANIA stent's Polyzene-F surface treatment promoted healthy endothelial cell growth and reduced platelet activation, leading to improved safety and economic benefits.
Research found that inherited and acquired risk factors play a significant role in abdominal venous thrombosis. Acquired risk factors were more common in patients with Superior Vena Cava Syndrome (SVT), while hereditary risk factors were similar in both BCS and SVT groups.
A recent study by the American Academy of Neurology found that people with migraines are more likely to develop venous thrombosis or blood clots in their veins. The research, which involved 574 participants in Italy, revealed a significant association between migraine and increased risk of blood clots.
Recent studies on DES have shown mixed results, with some suggesting increased risk of late thrombosis but no impact on mortality or myocardial infarction. However, other data indicate benefits in terms of reduced reinterventions and improved outcomes for high-risk patients.
A study found that male mice are more susceptible to blood clots due to sex-specific growth hormone secretion patterns. The researchers used a mouse model of thrombosis and discovered that pulsatile GH secretion in males protects against clot formation, while continuous GH secretion in females has the opposite effect.
A recent study published in The Lancet found that extended use of rivaroxaban significantly reduces the risk of venous thromboembolism after total hip arthroplasty, compared to short-term enoxaparin plus placebo. This finding has important implications for preventing blood clots in patients undergoing hip surgery.
A study found that drug-releasing stents decreased the need for repeat revascularization procedures by approximately 18% compared to bare-metal stents. The risk of death or heart attack also showed a small decrease, but no significant difference in overall mortality rates.
A retrospective cohort study of 10,000 patients aged 65 and older found that only 20% received thromboprophylaxis to prevent life-threatening venous thrombosis after discharge. Elderly patients have a 70% lower risk of dying within 3 months if they take an anticoagulant drug.
A recent study by McGill University Health Centre researchers found that only 19% of hip and knee replacement patients in Quebec received post-discharge antithrombotic treatment to prevent blood clots. This lack of treatment increases the risk of mortality for these patients, highlighting a need for improved care protocols.
A study found that clopidogrel reduced early thrombosis of new arteriovenous fistulas, but did not improve their maturity or suitability for use during dialysis. The treatment significantly reduced the risk of fistula thrombosis, but did not lead to a clinically meaningful increase in fistula patency.
A study found a strong association between air pollution and an increased risk of developing deep vein thrombosis, with higher exposure levels leading to faster clotting. The risk was stronger in men than women, highlighting the need for tighter air quality standards.
Research found that people who experienced strokes while fasting during Ramadan had a higher average number of strokes (5.5) compared to those not fasting (2.0). The study suggests coexistence of usual risk factors and dehydration may contribute to increased susceptibility to cerebral venous sinus thrombosis.
Researchers found that bioabsorbable everolimus-eluting stents were safe and effective in patients with single coronary artery lesions, with no late stent thromboses recorded. The study showed excellent procedural success rates and minimal formation of scar tissue within the stent.
A study examining long-term outcomes following blood clots found that patients with pulmonary embolism are at higher risk of experiencing recurrent clotting, major bleeding episodes, or death. The research also highlights the need for better anticoagulation strategies to reduce complications in the community setting.
A study comparing sirolimus-eluting and paclitaxel-eluting stents found no significant differences in heart attack or cardiac death rates among patients undergoing percutaneous coronary interventions. The use of drug-eluting stents may be safe for the general population, with low rates of serious adverse events at 18 months of follow-up.
A study of 2,471 patients with venous thrombosis found a three-fold greater relative risk associated with minor leg injuries that don't require surgery or extended bed rest. These injuries may increase blood clotting risk due to reduced activity and damage to blood vessel walls.
A new gene variant has been found to be more common in people with cerebral venous thrombosis than in healthy individuals. The study, published in Neurology, suggests that testing for this gene and using blood thinning medication may help prevent future blood clots.
Researchers compared computed tomographic pulmonary angiography (CTPA) to conventional lungs scans for excluding pulmonary embolism. While CTPA detected more clots, it also resulted in a higher rate of venous thromboembolism diagnoses. The study suggests that CTPA may be a safe and reliable alternative to ventilation-perfusion scanning.
Patients with non-cirrhotic and nontumoral extrahepatic portal vein obstruction often present with well-tolerated bleeding. Cirrhosis- and tumor-related portal vein thrombosis generally carries a grim prognosis. A large sample size study found that hypercoagulable states are less common in this population.
A cohort study of 8,755 employees found that long-haul flights significantly increased the risk of developing deep vein thrombosis. The researchers estimate that airline passengers are at least twice as likely to develop DVT during a long-haul flight compared to non-air travelers.
A meta-analysis of 38 trials and data from 18023 patients found that siromilus-eluting stents have a reduced risk of heart attack, with a 19% lower risk compared to bare-metal stents and a 17% lower risk compared to paclitaxel-eluting stents.
A meta-analysis of previous studies finds that both unfractionated and low-molecular-weight heparin are effective in preventing blood clots in hospitalized patients. Venous thromboembolism is a major cause of complications and death, with most cases occurring outside the hospital.
A study of 396 children who suffered a first cerebral venous thrombosis found that repeated venous thrombosis occurred in 22 cases, with 13 being cerebral, mostly in children over 2 years old and those without anti-coagulant treatment
A panel of experts shares their perspective on the causes of stent thrombosis, including early discontinuation of anticoagulation medication and stent fracture. The latest research on its prevention will also be discussed, highlighting the need for better strategies to solve this problem.
Contrast-enhanced ultrasound (CE-US) is highly accurate in identifying vascular and biliary complications after liver transplant, affecting up to 43.5% of patients. CE-US can accurately detect complications such as hepatic artery thrombosis, portal vein stenosis, and bile leaks.
Long-term safety of drug-eluting stents in off-label use shows low mortality rates, with cardiac mortality at 0.8%, but high risk of late stent thrombosis among non-responders to clopidogrel. The MATRIX Registry found that 34% of patients had diabetes and 33% a history of heart attack.
Researchers evaluated the safety and performance of a new bioabsorbable stent that eliminates several problems associated with metallic stents. At 30 days, device success was extremely high, and no patients experienced major adverse cardiac events or stent thrombosis.
A study comparing drug-eluting stents (DES) and bare-metal stents (BMS) found similar rates of complications, including stent thrombosis, MI, and mortality. However, DES patients had a slightly increased risk of stent thrombosis and heart attack between 12-15 months after implantation.